% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Weykamp:276766,
      author       = {F. Weykamp$^*$ and P. Hoegen$^*$ and S. Regnery$^*$ and E.
                      Katsigiannopulos and C. K. Renkamp and K. Lang and L. König
                      and E. Sandrini and E. Meixner and C. Rippke and C. Buchele
                      and J. Liermann and J. Debus$^*$ and S. Klüter and J.
                      Hörner-Rieber$^*$},
      title        = {{L}ong-{T}erm {C}linical {R}esults of {MR}-{G}uided
                      {S}tereotactic {B}ody {R}adiotherapy of {L}iver
                      {M}etastases},
      journal      = {Cancers},
      volume       = {15},
      number       = {10},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-01147},
      pages        = {2786},
      year         = {2023},
      note         = {#EA:E050#LA:E050#},
      abstract     = {(1) Background: Magnetic-resonance (MR)-guided stereotactic
                      body radiotherapy (SBRT) allows for ablative, non-invasive
                      treatment of liver metastases. However, long-term clinical
                      outcome data are missing. (2) Methods: Patients received
                      MR-guided SBRT with a MRIdian Linac between January 2019 and
                      October 2021 and were part of an ongoing prospective
                      observational registry. Local hepatic control (LHC), distant
                      hepatic control (DHC), progression free survival (PFS) and
                      overall survival (OS) were estimated with the Kaplan–Meier
                      method. Toxicity was documented according to CTCAE (v.5.0).
                      (3) Results: Forty patients were treated for a total of 54
                      liver metastases $(56\%$ with online plan adaptation).
                      Median prescribed dose was 50 Gy in five fractions equal to
                      a biologically effective dose (BED) (alpha/beta = 10 Gy) of
                      100 Gy. At 1 and 2 years, LHC was $98\%$ and $75\%,$ DHC was
                      $34\%$ and $15\%,$ PFS was $21\%$ and $5\%$ and OS was
                      $83\%$ and $57\%.$ Two-year LHC was higher in case of BED >
                      100 Gy $(100\%$ vs. $57\%;$ log-rank p = 0.04). Acute grade
                      1 and 2 toxicity (mostly nausea) occurred in $26\%$ and
                      $7\%$ of the patients, with no grade ≥ 3 event. (4)
                      Conclusions: To our knowledge, this is the largest cohort of
                      MR-guided liver SBRT. Long-term local control was promising
                      and underscores the aim of achieving >100 Gy BED.
                      Nonetheless, distant tumor control remains challenging.},
      cin          = {E050 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.3390/cancers15102786},
      url          = {https://inrepo02.dkfz.de/record/276766},
}